CP-751,871 Treatment For Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This study represents the first-in-human study for CP-751,871. The study aimed to define the
safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple
myeloma through a dose escalation design.